Table 2.

Comparison of LS values and FIB-4 scores between baseline, week 48, week 96, and week 144 in the overall population and the HBeAg-positive and -negative patients

	Baseline	Week 48		Week 96		Week 144
Overall population (n = 36)			P-value*		P-value*		P-value*
Liver stiffness measurement
Liver stiffness values (kPa)	13.8 (8.8–18.3)	8.7 (6.2–13.8)	< 0.001	6.5 (4.8–11.8)	< 0.001	6.4 (4.4–9.3)	< 0.001
Fibrosis stage			0.008		< 0.001		< 0.001
Mild fibrosis	9 (25.0)	19 (52.8)		24 (66.7)		29 (80.6)
Significant fibrosis	27 (75.0)	17 (47.2)		12 (33.3)		7 (19.4)
FIB-4	2.3 (1.7–4.5)	1.4 (1.0–2.6)	0.06	1.1 (0.8–2.7)	0.03	1.2 (0.8–2.1)	0.01
HBeAg-positive patients (n = 19)
Liver stiffness measurement
Liver stiffness values (kPa)	14.4 (9.6–28.9)	10.5 (5.3–16.9)	< 0.001	7.7 (4.6–12.0)	< 0.001	5.7 (3.5–9.3)	< 0.001
Fibrosis stage			0.06		0.03		0.008
Mild fibrosis	4 (21.1)	9 (47.4)		12 (63.2)		15 (78.9)
Significant fibrosis	15 (78.9)	10 (52.6)		7 (36.8)		4 (21.1)
FIB-4	2.3 (1.6–4.6)	1.3 (1.0–3.8)	0.05	1.1 (0.7–3.4)	0.006	1.1 (0.8–3.0)	0.005
HBeAg-negative patients (n = 17)
Liver stiffness measurement
Liver stiffness values (kPa)	12.1 (7.1–17.2)	8.6 (6.4–12.3)	0.03	6.3 (5.3–11.7)	0.002	6.6 (4.9–9.0)	0.003
Fibrosis stage			0.25		0.03		0.008
Mild fibrosis	5 (29.4)	10 (58.8)		12 (70.6)		14 (82.4)
Significant fibrosis	12 (70.6)	7 (41.2)		5 (29.4)		3 (17.6)
FIB-4	2.3 (1.8–3.6)	1.5 (1.1–2.1)	0.68	1.1 (0.8–2.2)	0.50	1.4 (0.9–1.6)	0.39

NOTE: Variables are expressed as median (interquartile range) or n (%).

Abbreviations: FIB-4, Fibrosis-4; HBeAg, hepatitis B e antigen.

*Calculated compared to baseline value.